Phio Pharmaceuticals Corp.
Close on Oct 19, 2026
- Market cap
- $10.09M
- P/E (TTM)
- –
- Dividend yield
- –
About Phio Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics to treat various forms of cancer. Its work centers on its proprietary INTASYL small interfering RNA gene-silencing technology, which enhances the capacity of immune cells to eliminate tumor cells without requiring specialized drug formulations or delivery mechanisms. The company operates within a single business segment, directing its pipeline toward cancer patients. Its investigational product candidates include PH-762, designed to target the PD-1 protein for the treatment of cutaneous carcinomas, and PH-894, designed to silence the BRD4 protein.
Phio Pharmaceuticals conducts its clinical and development activities primarily within the United States. Its lead drug candidate, PH-762, undergoes clinical evaluation through a multi-center Phase 1b trial across American clinical sites. In addition, the company secures drug substance development and manufacturing services through a contract manufacturer based in the United States. The enterprise maintains its principal executive offices and corporate headquarters in King of Prussia, Pennsylvania.
Summary of the business section of Phio Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Phio Pharmaceuticals Corp.
- Founded
- 2011
- Headquarters
- King Of Prussia, PA
- Address
- 411 Swedeland Road, Suite 23-1080 19406
- Phone
- (508) 767-3861
- Website
- phiopharma.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- PHIO
- Exchange
- Nasdaq
- IPO date
- May 10, 2012
- Shares outstanding
- 12M, Aug 4, 2026
- Public float
- $11.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-9 reverse, Aug 14, 2024; 1-for-9 reverse, Jul 5, 2024; 1-for-12 reverse, Mar 22, 2023; 1-for-12 reverse, Jan 26, 2023; 1-for-55 reverse, Jan 15, 2020; 1-for-55 reverse, Jan 15, 2020; 1-for-10 reverse, Mar 26, 2018; 1-for-10 reverse, Jan 8, 2018; 1-for-10 reverse, Apr 18, 2016; 1-for-10 reverse, Apr 14, 2016; 1-for-30 reverse, Jul 24, 2013; 1-for-30 reverse, Jul 18, 2013
- SEC CIK
- 1533040
- CUSIP
- 71880W501
- ISIN
- US71880W5013
- LEI
- 549300KOGMLSPLDVHR52
- EIN
- 45-3215903
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert J. Bitterman | Chairman, Pres. & CEO, Director | 764,871 |
| Lisa Cabott Carson | Chief Financial Officer | 189,112 |
| Ronald Todd Plott | Director | 42,000 |
| Patricia A. Bradford | Director | 64,151 |
| David H. Deming | Director | 37,800 |
| Curtis Lockshin | Director | 35,155 |
| Jonathan E. Freeman | Director | 32,655 |
| Robert L. Ferrara | Director | 38,666 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.16M | $885.95K | $599.70K | $19 | – |
| FY2024 | $387.02K | $384.55K | $105.21K | $23 | – |
| FY2023 | $437.89K | $379.39K | $0 | $6 | – |
| FY2022 Robert M. Infarinato | $109.38K | $94.72K | $0 | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had six full-time employees, all of whom work primarily on a remote basis.”
Corporate history
Events identified from SEC filings